Cost of supportive cancer care in the Russian Federation. Part 2
Year: 2024
Type: article
Abstract: Objective. To assess the cost of supportive drug therapy for 10 complications of malignant neoplasms according to the recommendations of the Russian Public Organization «Russian Society of Clinical Oncology» (RUSSCO). Material and methods. Considering the RUSSCO recommendations, we estimated drug therapy regimens for the following complications: anemia, hepatotoxicity, dermatological reactions, cardiovascular toxicity, neurological complications, nephrotoxicity, effects of extravasation, febrile neutropenia, nausea and vomiting, central venous access. To estimate the population requiring supportive therapy, we used data from registers of medical care bills for 2022. These reports contain information on the number of completed cases of antitumor drug therapy and the number of patients who received treatment. Literature data on the incidence of the above-mentioned complications were also used. Results. The largest financial costs (63.8% of all complications) were observed for the treatment of anemia (4 721 896 721.06 rubbles), hepatotoxicity (3 545 843 422.82 rubbles) and consequences of extravasation (2 388 137 692.57 rubbles). The oncology profile accounts for 66% of the estimated funding within this model. In the current model, 34% of the need is for preferential drug provision, 37% is additional need for compulsory medical insurance to finance the added cost of hospital-stay in a day hospital and 31% in a 24-hour hospital. Conclusion. These findings complement the previously published results for other complications presented in the RUSSCO recommendations. Calculation methodology and appropriate data can underlie further improvement of financing of supportive cancer therapy.
Authors: I.A. Zheleznyakova, E.I. Rumyantseva, O.S. Plakhotnik, I.A. Alexandrov, T.S. Vakhrusheva, G.V. Trifonova, E.A. Sidorova, A.S. Yakina, E.S. Samsonova, I.A. Mikhailov, Ya.A. Azarova, Yu.V. Buydenok, M.V. Vitsenya, L.Yu. Vladimirova, O.A. Gladkov, E.G. Gromova, D.M. Dubovichenko, E.V. Zamkova, R.A. Zukov, A.Z. Isyangulova, E.V. Karabina, V.V. Karaseva, I.A. Koroleva, S.I. Kutukova, S.A. Laletina, D.Kh. Latipova, A.V. Mishina, O.Yu. Novikova, D.A. Nosov, E.G. Ovchinnikova, R.V. Orlova, V.V. Petkau, A.A. Plykina, D.D. Sakaeva, G.B. Statsenko, P.E. Tkachenko, A.A. Tryakin, A.V. Fateeva, N.P. Khudorozhkova, S.A. Tyulyandin, V.V. Omelyanovskiy
Institutions: Russian Medical Academy of Continuous Professional Education, National Research Institute of Public Health named after N.A. Semashko, Russian Cancer Research Center NN Blokhin, National Medical Research Center of Cardiology, Arkhangel'skiy Klinicheskiy Onkologicheskiy Dispanser, Krasnoyarsk State Medical University, Republican Oncological Clinical Dispensary, Guz "Tul'skiy Oblastnoy Onkologicheskiy Dispanser, Pirogov Russian National Research Medical University, Samara Medical Institute Reaviz, First Pavlov State Medical University of St. Petersburg, City Clinical Oncology Center, Institute of Oncology NN Petrov, Central Clinical Hospital and Polyclinic, Nizhny Novgorod Regional Clinical Oncology Center, St Petersburg University, Ural State Medical University, Russian Society of Clinical Oncology, Sechenov University
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: diamond
OpenAlex ID: W4405364367